DNMT3A and cyclic hematopoiesis: We observed that neither group (Fig. 5d,e and Supplementary Table 7) had altered rates of DNMT3A-R882-mutant CH (OR = 0.90 (95% Cl, 0.34–2.40), P = 0.83 and OR = 0.82 (95% Cl, 0.45–1.49), P = 0.52, respectively), indicating that T2D per se does not significantly alter DNMT3A-R882-mutant CH risk.